OrigiMed is a Shanghai, China-based company focusing on the development of new oncology assays.
The latest round, led by Northpond Ventures, brings the total amount raised by the
company to date to $76 million.
The firm will use the proceeds to accelerate commercialization and deployment of its microfluidic technology and for working capital purposes.
Net proceeds from the exercise of subscription rights and warrants are anticipated to be $22.6 million, excluding any proceeds from the exercise of warrants.
Qiagen and Health Innovation Manchester will create a genomics campus in the district anchored by a diagnostics development hub.
The molecular diagnostics company previously raised $180 million in its 2015 initial public offering.
It anticipates using the funds to complete the development of its first set of diagnostic products, and for a set of clinical studies to obtain regulatory clearance.
The PGx decision support software that Sonic is adopting includes clinical reporting for 65 genes and can be tailored to a variety of clinical specialties.
The partners will test PerkinElmer's Vanadis NIPT platform on samples from 2,650 women to determine detection and false positive rates.
The companies will combine their respective services into a single end-to-end offering for microbiome research.
Analyst Puneet Souda said HTG has a growing funnel of biopharma projects that have the potential to convert to companion diagnostics with regulatory approval.
The Beijing-based firm said it will use the funding for research and development, to obtain additional intellectual property, and to pursue its strategic goals.
DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
The Slovenia-based firm will use the funds to develop its Health Intelligence platform, expand into Asian markets, and open an office in the UK.
The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.
The government says it is using DNA testing as part of efforts to reunite families by court-ordered deadlines, but it will not reveal which lab is performing testing.
The center is an international joint venture established in 2013 between South Korean clinical lab Eone Life Science and California-based Diagnomics.
The German Federal Joint Committee (G-BA) plans to decide on reimbursement of breast cancer biomarker tests in Q4.
The FDA said that pooled testing of donations using a screening test that it has licensed is a sufficient method for complying with its testing regulations.
Under the new collaboration, Predicine will use its GeneRADAR technology to aid Kintor in the development and advancement of novel drugs.
Cancer researcher Alan Rabson has died at 92, the New York Times reports.
As the National Guideline Clearinghouse goes dark, the ECRI Institute says it will pick up the slack.
In Genome Research this week: sequencing method examines proteins parasite uses to evade immune system, L1 insertions in cancer, and more.
The Atlantic reports on private Facebook support groups for people who receive unexpected parentage results from direct-to-consumer genetic tests.